Chimeric antigen receptor (CAR) T cell therapy has revolutionized treatment for hematological malignancies, yet translating this success to solid tumors remains challenging. Major obstacles include antigen heterogeneity, on-target off-tumor toxicity, limited infiltration and persistence, and the immunosuppressive tumor microenvironment (TME). The present review discusses recent engineering strategies designed to overcome these barriers. Innovations such as affinity-tuned and logic-gated CARs improve specificity and safety, while multi-antigen targeting helps address tumor heterogeneity by avoiding antigen escape. Gene-editing approaches enhance CAR T cell fitness by promoting memory phenotypes, metabolic resilience, and resistance to inhibitory signals imposed by the immunosuppressive TME. Additional modifications improve trafficking, enable extracellular matrix degradation, and reprogram CAR T cells to withstand the hostile conditions of the TME. Together, these advances reflect a growing shift toward rational CAR design and synthetic immunology, with the goal of achieving durable and safe responses in solid tumors. Early clinical trials show promise, and continued translational efforts will be key to unlocking the full therapeutic potential of CAR T cells in this setting.
Get full access to this article
View all access options for this article.
References
1.
DagarG, GuptaA, MasoodiT, et al.Harnessing the potential of CAR-T cell therapy: Progress, challenges, and future directions in hematological and solid tumor treatments. J Transl Med, 2023; 21(1):449; doi: 10.1186/s12967-023-04292-3
2.
ParkS, MausMV, ChoiBD. CAR-T cell therapy for the treatment of adult high-grade gliomas. NPJ Precis Oncol, 2024; 8(1):279; doi: 10.1038/s41698-024-00753-0
3.
BrownCE, HibbardJC, AlizadehD, et al.Locoregional delivery of IL-13Ralpha2-targeting CAR-T cells in recurrent high-grade glioma: A phase 1 trial. Nat Med, 2024; 30(4):1001–1012; doi: 10.1038/s41591-024-02875-1
4.
VitanzaNA, RonsleyR, ChoeM, et al.Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: A phase 1 trial. Nat Med, 2025; 31(3):861–868; doi: 10.1038/s41591-024-03451-3
5.
QiC, LiuC, PengZ, et al.Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): A randomised, open-label, phase 2 trial. Lancet, 2025; 405(10494):2049–2060; doi: 10.1016/S0140-6736(25)00860-8
6.
GustJ, ColeBL, RonsleyR, et al.Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS Tumors: Results of the completed BrainChild02 Phase 1 Clinical Trial. Neuro Oncol, 2025:noaf064; doi: 10.1093/neuonc/noaf064
7.
BagleySJ, BinderZA, LamraniL, et al.Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: A phase 1 trial. Nat Cancer, 2024; 5(3):517–531; doi: 10.1038/s43018-023-00709-6
8.
ChoiBD, GerstnerER, FrigaultMJ, et al.Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N Engl J Med, 2024; 390(14):1290–1298; doi: 10.1056/NEJMoa2314390
9.
HegdeM, NavaiS, DeRenzoC, et al.Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer, 2024; 5(6):880–894; doi: 10.1038/s43018-024-00749-6
10.
MonjeM, MahdiJ, MajznerR, et al.Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature, 2025; 637(8046):708–715; doi: 10.1038/s41586-024-08171-9
11.
DorffTB, BlanchardMS, AdkinsLN, et al.PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med, 2024; 30(6):1636–1644; doi: 10.1038/s41591-024-02979-8
12.
Del BufaloF, De AngelisB, CaruanaI, et al.; Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med, 2023; 388(14):1284–1295; doi: 10.1056/NEJMoa2210859
13.
MackensenA, HaanenJB, KoeneckeC, et al.CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med, 2023; 29(11):2844–2853; doi: 10.1038/s41591-023-02612-0
14.
FuQ, ZhengY, FangW, et al.RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: A phase I trial. EClinicalMedicine, 2023; 63:102175; doi: 10.1016/j.eclinm.2023.102175
15.
NarayanV, Barber-RotenbergJS, JungI-Y, et al.PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med, 2022; 28(4):724–734; doi: 10.1038/s41591-022-01726-1
16.
AdusumilliPS, ZaudererMG, RivièreI, et al.A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. Cancer Discov, 2021; 11(11):2748–2763; doi: 10.1158/2159-8290.CD-21-0407
17.
BrudnoJN, KochenderferJN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol, 2024; 21(7):501–521; doi: 10.1038/s41571-024-00903-0
18.
FlugelCL, MajznerRG, KrenciuteG, et al.Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol, 2023; 20(1):49–62; doi: 10.1038/s41571-022-00704-3
19.
PangN, ShiJ, QinL, et al.IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol, 2021; 14(1):118; doi: 10.1186/s13045-021-01128-9
20.
PoseyADJr, SchwabRD, BoesteanuAC, et al.Engineered CAR T cells targeting the cancer-associated Tn-Glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity, 2016; 44(6):1444–1454; doi: 10.1016/j.immuni.2016.05.014
21.
LiS, ZhangM, WangM, et al.B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer. Cell Death Discov, 2023; 9(1):147; doi: 10.1038/s41420-023-01453-7
22.
MajznerRG, TheruvathJL, NellanA, et al.CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res, 2019; 25(8):2560–2574; doi: 10.1158/1078-0432.CCR-18-0432
23.
Daei SorkhabiA, Mohamed KhosroshahiL, SarkeshA, et al.The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Front Immunol, 2023; 14:1113882; doi: 10.3389/fimmu.2023.1113882
24.
HaasAR, GoldenRJ, LitzkyLA, et al.Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Mol Ther, 2023; 31(8):2309–2325; doi: 10.1016/j.ymthe.2023.06.006
25.
MorganRA, YangJC, KitanoM, et al.Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther, 2010; 18(4):843–851; doi: 10.1038/mt.2010.24
26.
LiCH, SharmaS, HeczeyAA, et al.Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med, 2025; 31(4):1125–1129; doi: 10.1038/s41591-025-03513-0
27.
Martin-OtalC, NavarroF, CasaresN, et al.Impact of tumor microenvironment on adoptive T cell transfer activity. Int Rev Cell Mol Biol, 2022; 370:1–31; doi: 10.1016/bs.ircmb.2022.03.002
28.
ZhuX, ChenJ, LiW, et al.Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors. Cancer Res, 2024; 84(1):84–100; doi: 10.1158/0008-5472.CAN-23-1038
29.
SchreiberY, LeonardJ. Hypoxia-responsive synthetic gene circuits to improve safety and potency of CAR T cell therapy for solid tumors. Jco, 2024; 42(23_suppl):37–37; doi: 10.1200/JCO.2024.42.23_suppl.37
30.
ShabanehTB, StevensAR, StullSM, et al.Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity. J Immunother Cancer, 2024; 12(2):e008566; doi: 10.1136/jitc-2023-008566
31.
YangY, VedvyasY, AlcainaY, et al.Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity. JCI Insight, 2024; 9(22):e186268; doi: 10.1172/jci.insight.186268
32.
HegdeM, MukherjeeM, GradaZ, et al.Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest, 2016; 126(8):3036–3052; doi: 10.1172/JCI83416
33.
BassanD, WeinbergerL, YiJ, et al.HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity. J Immunother Cancer, 2023; 11(12):e007426; doi: 10.1136/jitc-2023-007426
34.
VogtKC, SilbermanPC, LinQ, et al.Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. Sci Adv, 2025; 11(4):eads3403; doi: 10.1126/sciadv.ads3403
35.
TousleyAM, RotirotiMC, LabaniehL, et al.Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature, 2023; 615(7952):507–516; doi: 10.1038/s41586-023-05778-2
36.
FraessleSP, TschulikC, EffenbergerM, et al.Activation-inducible CAR expression enables precise control over engineered CAR T cell function. Commun Biol, 2023; 6(1):604; doi: 10.1038/s42003-023-04978-w
37.
ZhangRY, WeiD, LiuZK, et al.Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma therapy. Front Cell Dev Biol, 2019; 7:233; doi: 10.3389/fcell.2019.00233
38.
MajznerRG, MackallCL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov, 2018; 8(10):1219–1226; doi: 10.1158/2159-8290.CD-18-0442
39.
HegdePS, ChenDS. Top 10 challenges in cancer immunotherapy. Immunity, 2020; 52(1):17–35; doi: 10.1016/j.immuni.2019.12.011
40.
HamiehM, Mansilla-SotoJ, RiviereI, et al.Programming CAR T cell tumor recognition: Tuned antigen sensing and logic gating. Cancer Discov, 2023; 13(4):829–843; doi: 10.1158/2159-8290.CD-23-0101
41.
CarusoHG, HurtonLV, NajjarA, et al.Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res, 2015; 75(17):3505–3518; doi: 10.1158/0008-5472.CAN-15-0139
42.
RichmanSA, Nunez-CruzS, MoghimiB, et al.High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer Immunol Res, 2018; 6(1):36–46; doi: 10.1158/2326-6066.CIR-17-0211
43.
HamiehM, DobrinA, CabrioluA, et al.CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature, 2019; 568(7750):112–116; doi: 10.1038/s41586-019-1054-1
44.
MeiA, LetscherKP, ReddyS. Engineering next-generation chimeric antigen receptor-T cells: Recent breakthroughs and remaining challenges in design and screening of novel chimeric antigen receptor variants. Curr Opin Biotechnol, 2024; 90:103223; doi: 10.1016/j.copbio.2024.103223
45.
BagleySJ, DesaiAS, FraiettaJA, et al.Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Ralpha2 in recurrent glioblastoma: a phase 1 trial. Nat Med, 2025; doi: 10.1038/s41591-025-03745-0
46.
LiuX, JiangS, FangC, et al.Affinity-Tuned ErbB2 or EGFR chimeric antigen receptor t cells exhibit an increased therapeutic index against tumors in mice. Cancer Res, 2015; 75(17):3596–3607; doi: 10.1158/0008-5472.CAN-15-0159
47.
WagnerDL, FritscheE, PulsipherMA, et al.Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol, 2021; 18(6):379–393; doi: 10.1038/s41571-021-00476-2
48.
AhmedN, BrawleyV, HegdeM, et al.HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol, 2017; 3(8):1094–1101; doi: 10.1001/jamaoncol.2017.0184
49.
KolluriA, LiD, LiN, et al.Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC. Hepatol Commun, 2023; 7(2):e0022; doi: 10.1097/HC9.0000000000000022
50.
KennewickKT, YamaguchiY, GibsonJ, et al.Nonsignaling extracellular spacer regulates tumor antigen selectivity of CAR T cells. Mol Ther Oncol, 2024; 32(2):200789; doi: 10.1016/j.omton.2024.200789
51.
CastellettiL, YeoD, van ZandwijkN, et al.Anti-mesothelin CAR T cell therapy for malignant mesothelioma. Biomark Res, 2021; 9(1):11; doi: 10.1186/s40364-021-00264-1
52.
BarrettAM, BrittonZT, CarrascoRA, et al.Preclinical evaluation of AZD6422, an armored chimeric antigen receptor T cell targeting CLDN18.2 in gastric, pancreatic, and esophageal cancers. Clin Cancer Res, 2024; 30(23):5413–5429; doi: 10.1158/1078-0432.CCR-24-1853
53.
SampsonJH, ChoiBD, Sanchez-PerezL, et al.EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res, 2014; 20(4):972–984; doi: 10.1158/1078-0432.CCR-13-0709
54.
LiuXF, OndaM, SchlomerJ, et al.Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope. Proc Natl Acad Sci USA, 2024; 121(4):e2317283121; doi: 10.1073/pnas.2317283121
55.
MurayamaY, KawashimaH, KuboN, et al.Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma. Transl Oncol, 2021; 14(12):101227; doi: 10.1016/j.tranon.2021.101227
56.
GuedanS, ChenX, MadarA, et al.ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood, 2014; 124(7):1070–1080; doi: 10.1182/blood-2013-10-535245
57.
KawalekarOU, O’ConnorRS, FraiettaJA, et al.Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity, 2016; 44(2):380–390; doi: 10.1016/j.immuni.2016.01.021
58.
LiuY, LiuG, WangJ, et al.Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med, 2021; 13(586):eabb5191; doi: 10.1126/scitranslmed.abb5191
59.
FeuchtJ, SunJ, EyquemJ, et al.Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med, 2019; 25(1):82–88; doi: 10.1038/s41591-018-0290-5
60.
ObajdinJ, Larcombe-YoungD, GloverM, et al.Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells. Cell Rep Med, 2024; 5(11):101827; doi: 10.1016/j.xcrm.2024.101827
61.
GuoX, JiangH, ShiB, et al.Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma. Front Pharmacol, 2018; 9:1118; doi: 10.3389/fphar.2018.01118
62.
PatelRP, GhilardiG, ZhangY, et al.CD5 deletion enhances the antitumor activity of adoptive T cell therapies. Sci Immunol, 2024; 9(97):eadn6509; doi: 10.1126/sciimmunol.adn6509
63.
LynnRC, WeberEW, SotilloE, et al.c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature, 2019; 576(7786):293–300; doi: 10.1038/s41586-019-1805-z
64.
TangN, ChengC, ZhangX, et al.TGF-beta inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight, 2020; 5(4):e133977; doi: 10.1172/jci.insight.133977
65.
JainN, ZhaoZ, FeuchtJ, et al.TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature, 2023; 615(7951):315–322; doi: 10.1038/s41586-022-05692-z
66.
BelkJA, DanielB, SatpathyAT. Epigenetic regulation of T cell exhaustion. Nat Immunol, 2022; 23(6):848–860; doi: 10.1038/s41590-022-01224-z
67.
DoanA, MuellerKP, ChenA, et al.FOXO1 is a master regulator of CAR T memory programming. Res Sq, 2023; doi: 10.2120/3/rs.3.rs-2802998/v1
68.
LiL, LiQ, YanZ-X, et al.Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells. Sci Rep, 2022; 12(1):12506; doi: 10.1038/s41598-022-16616-2
69.
LanitisE, RotaG, KostiP, et al.Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. J Exp Med, 2021; 218(2):e20192203; doi: 10.1084/jem.20192203
70.
Sanchez-MorenoI, Lasarte-CiaA, Martin-OtalC, et al.Tethered IL15-IL15Ralpha augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model. J Immunother Cancer, 2024; 12(7):e008572; doi: 10.1136/jitc-2023-008572
71.
PoorebrahimM, MeliefJ, Pico de CoanaY, et al.Counteracting CAR T cell dysfunction. Oncogene, 2021; 40(2):421–435; doi: 10.1038/s41388-020-01501-x
72.
UsluU, JuneCH. Beyond the blood: Expanding CAR T cell therapy to solid tumors. Nat Biotechnol, 2025; 43(4):506–515; doi: 10.1038/s41587-024-02446-2
73.
AndreaAE, ChironA, MallahS, et al.Advances in CAR-T cell genetic engineering strategies to overcome hurdles in solid tumors treatment. Front Immunol, 2022; 13:830292; doi: 10.3389/fimmu.2022.830292
74.
AkbariP, KatsarouA, DaghighianR, et al.Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors. Biochim Biophys Acta Rev Cancer, 2022; 1877(3):188701; doi: 10.1016/j.bbcan.2022.188701
75.
PievaniA, BiondiM, TettamantiS, et al.CARs are sharpening their weapons. J Immunother Cancer, 2024; 12(1):e008275; doi: 10.1136/jitc-2023-008275
76.
ZhangZ, LiuC, YangZ, et al.CAR-T-cell therapy for solid tumors positive for fibronectin extra domain B. Cells, 2022; 11(18):2863; doi: 10.3390/cells11182863
77.
Martin-OtalC, Lasarte-CiaA, SerranoD, et al.Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells. J Immunother Cancer, 2022; 10(8):e004479; doi: 10.1136/jitc-2021-004479
78.
SwanSL, MehtaN, IlichE, et al.IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma. Front Immunol, 2023; 14:1085547; doi: 10.3389/fimmu.2023.1085547
79.
YangY, YangH, AlcainaY, et al.Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models. Nat Commun, 2023; 14(1):2068; doi: 10.1038/s41467-023-37646-y
80.
PengL, SferruzzaG, YangL, et al.CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol, 2024; 21(10):1089–1108; doi: 10.1038/s41423-024-01207-0
81.
WangZ, ShangJ, QiuY, et al.Suppression of the METTL3-m(6)A-integrin beta1 axis by extracellular acidification impairs T cell infiltration and antitumor activity. Cell Rep, 2024; 43(2):113796; doi: 10.1016/j.celrep.2024.113796
82.
DuB, QinJ, LinB, et al.CAR-T therapy in solid tumors. Cancer Cell, 2025; 43(4):665–679; doi: 10.1016/j.ccell.2025.03.019
83.
NavarroF, CasaresN, Martin-OtalC, et al.Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy. Oncoimmunology, 2022; 11(1):2070337; doi: 10.1080/2162402X.2022.2070337
84.
HuW, LiF, LiangY, et al.Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors. J Immunother Cancer, 2025; 13(1):e010540; doi: 10.1136/jitc-2024-010540
85.
SchildT, WallischP, ZhaoY, et al.Metabolic engineering to facilitate anti-tumor immunity. Cancer Cell, 2025; 43(3):552–562 e9; doi: 10.1016/j.ccell.2025.02.004
86.
PanettiS, McJannettN, FultangL, et al.Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment. Blood Adv, 2023; 7(9):1754–1761; doi: 10.1182/bloodadvances.2022008272
87.
MoralyJ, KondoT, BenzaouiM, et al.Metabolic dialogues: Regulators of chimeric antigen receptor T cell function in the tumor microenvironment. Mol Oncol, 2024; 18(7):1695–1718; doi: 10.1002/1878-0261.13691
88.
NewickK, O’BrienS, SunJ, et al.Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase A localization. Cancer Immunol Res, 2016; 4(6):541–551; doi: 10.1158/2326-6066.CIR-15-0263
89.
YangQ, HaoJ, ChiM, et al.D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment. Mol Ther, 2022; 30(3):1188–1200; doi: 10.1016/j.ymthe.2022.01.007
90.
WuZ, WangH, ZhengZ, et al.IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor microenvironment. J Transl Med, 2025; 23(1):275; doi: 10.1186/s12967-025-06276-x
91.
SchauerMP, WeberJ, AltieriB, et al.Autocrine signaling in hormonally active cancer induces antigen expression for immunotherapy. bioRxiv, 2025; 2025; doi: 10.1101/2025.01.28.632923
